癌症检测公司Guardant Health（股票代码：GH）周四盘中股价大涨27.45%，创下近期新高。这一显著涨幅主要源于公司发布的第三季度财报远超市场预期，极大提振了投资者信心。
根据公司公布的财报显示，Guardant Health第三季度收入达到2.652亿美元，明显高于分析师预期的2.357亿美元。更值得注意的是，公司报告调整后每股亏损为0.39美元，大幅好于市场预期的0.76美元亏损。这一业绩表现不仅超出了华尔街分析师的预测，也展现了公司强劲的业务增长势头。
受此利好消息影响，多家券商纷纷上调了Guardant Health的目标价。其中，Canaccord Genuity将公司的目标价从75美元大幅上调至100美元，Leerink Partners也将目标价从85美元上调至100美元。分析师普遍认为，Guardant Health在癌症液体活检技术领域的领先地位，以及其业务的持续改善，将为公司未来的增长提供强劲动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.